Evidence suggests that it is unlikely for CD40 monoclonal antibodies to exhibit substantial single-agent anti-tumor activity in PDAC patients; further studies are thus required to develop effective combinations of CD40 agonist therapy with chemotherapy, RT or other forms of immunotherapy [133]. Here, CD40 is linked to neoplasm.